Notable Labs Ltd
NASDAQ:NTBL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Notable Labs Ltd
Cash from Operating Activities
Notable Labs Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Notable Labs Ltd
NASDAQ:NTBL
|
Cash from Operating Activities
-$16.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Operating Activities
$25.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash from Operating Activities
-$10.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Operating Activities
-$162.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Operating Activities
-$7.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash from Operating Activities
-$20.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
Notable Labs Ltd
Glance View
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
See Also
What is Notable Labs Ltd's Cash from Operating Activities?
Cash from Operating Activities
-16.9m
USD
Based on the financial report for Jun 30, 2024, Notable Labs Ltd's Cash from Operating Activities amounts to -16.9m USD.
What is Notable Labs Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-6%
Over the last year, the Cash from Operating Activities growth was 4%. The average annual Cash from Operating Activities growth rates for Notable Labs Ltd have been 9% over the past three years , -6% over the past five years .
